International Journal of Biochemistry Research & Review

Bacterial cancer therapy has re-entered mainstream oncology through engineered Salmonella, Clostridium and Escherichia coli platforms, yet clinical returns have remained modest and dominated by toxicity. Against this background, a recent preclinical report describing complete tumour regression in every treated animal after a single intravenous dose of Ewingella americana isolated from the gut of the Japanese tree frog Dryophytes japonicus represents an unusually strong efficacy claim from an unusually unexamined source. This review provides the first independent critical appraisal of that claim. It defines the state of evidence for amphibian gut-derived bacterial therapeutics, evaluates the internal and external validity of the supporting experiments, tests the proposed dual cytotoxic and immunomodulatory mechanism against the wider literature on tumour-targeting bacteria, and assesses translational feasibility. Literature was identified through structured searching of biomedical, multidisciplinary and discipline-specific scholarly sources, supplemented by backward and forward citation tracking and by authoritative nomenclature and genomic resources. The synthesis indicates that the efficacy signal rests on a single laboratory, a single subcutaneous syngeneic colorectal model, small group sizes and a vehicle-mismatched control, and that the therapeutic isolate was identified by partial ribosomal gene sequencing while its virulence repertoire was inferred from a reference type strain rather than sequenced directly. The characterisation of the organism as naturally non-pathogenic is difficult to reconcile with a documented record of human bacteraemia, meningitis, peritonitis and sepsis, with phytopathogenic activity in cultivated mushrooms, and with its formal biological risk classification. Mechanistic attribution to hypoxia-driven colonisation and pattern-recognition-receptor-mediated innate activation remains plausible but underdetermined, and the reported neutrophil dependence conflicts with evidence from an established anaerobic platform. Interspecies differences in endotoxin sensitivity, a therapeutic window in which the effective dose coincides with the maximum tolerated dose, and unresolved strain-characterisation and access-and-benefit-sharing obligations together constitute substantial barriers. The discovery is best regarded as a hypothesis-generating proof of concept requiring independent replication before translational claims are advanced.